Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Share:
Related MRK
Favorable News On Keytruda Drives Piper Jaffray's Upgrade Of Merck
8 Biggest Price Target Changes For Thursday
Dynavax Technologies: Valuation Of The Immune-Oncology Pipeline (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Merck & Co. (NYSE: MRK), but lowered its price target from $49.00 to $47.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Merck & Co. closed on Tuesday at $43.34.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2017GuggenheimUpgradesNeutralBuy
Jan 2017Morgan StanleyUpgradesEqual-WeightOverweight
Dec 2016JefferiesDowngradesHoldUnderperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!